Key clinical point: Bimekizumab demonstrated superior efficacy than placebo and had an acceptable safety profile in patients with psoriatic arthritis (PsA).
Major finding: Bimekizumab vs placebo led to a significantly higher response rate for minimal disease activity (risk ratio [RR], 4.188; P < .001), ≥ 70% improvement in the American College of Rheumatology criteria (RR, 7.932; P < .0001). Bimekizumab was superior to placebo in achieving ACR20/50/70 response at a dose of 160 mg. The risk for treatment-emergent adverse events was modestly higher with bimekizumab vs placebo (RR, 1.423; P = .023), whereas that for serious malignancies, upper respiratory tract infection, injection site reactions, and pharyngitis was similar for both.
Study details: This meta-analysis of four placebo-controlled randomized clinical trials included 1323 patients with PsA (age, ≥ 18 years), of whom 853 received bimekizumab.
Disclosures: This study was supported by the National Science Foundation of China and the Natural Science Foundation of Shanxi Province. The authors declared no conflict of interests.
Source: Su QY, Yang L, Cao TY, et al. Efficacy and safety of bimekizumab in the treatment of psoriatic arthritis: A systematic review and meta-analysis . Expert Opin Drug Saf. Published online April 23, 2024 . Source